Adoptive cell transfer (ACT) is an emerging and promising cancer immunotherapy that has been improved through various approaches. Here, we described the distinctive characteristics and functions of tumor Ag-specific effector CD8
Introduction
Adoptive cell transfer (ACT) has been emerging as a promising cancer immunological therapy. In ACT therapies, an autologous tumor-reactive T-cell population is expanded to a large number of cells via ex vivo T-cell generation, before being transferred back to the patient. 1, 2 There have been two approaches adopted with the aim of optimizing adoptive immunotherapy for the treatment of cancer, namely preparing the recipient's body to improve antitumor immune reactions, and improving the tumor-specific T-cells to be transferred. In the first method, recipients are conditioned via irradiation, [3] [4] [5] chemotherapy 4, 6 or stimulatory/inhibitory signal modulation 2, 7, 8 to establish a more preferable environment for adoptive T-cells to function. Alternatively, the second method aims to create more efficacious T-cell clones by modified in vitro expansion [9] [10] [11] or through genetic techniques, [12] [13] [14] which act upon the candidate T-cells before use in ACT. OX40 (CD134, TNFRSF4), a member of the TNFR (tumor necrosis factor receptor) superfamily, is well known for its costimulatory function after binding and activation by OX40 ligand occurs. 15, 16 OX40 can be induced on both activated CD4 1 and CD8 1 T-cells. Signaling through OX40 has been found to be beneficial for T-cell expansion in vivo following antigen recognition. [17] [18] [19] In immunization models, it has been proven that OX40 co-stimulation increases both the populations and activities of CD4 1 and CD8 1 effector T-cells by promoting helper T-cell function 16, 20 and abrogating regulatory T-cell suppression. 21, 22 OX40 co-stimulation can also directly enhance the functions of Ag-specific CD8 1 T-cells, even in the absence of helper T-cells. 23 OX40 and OX40 ligand interactions can determine the expansion of CD8 1 T-cells and function to maintain cytotoxic T lymphocyte (CTL) survival during responses to Ag, and therefore, can confer CTL-mediated protection against tumor growth. 24 Moreover, the prolonged in vivo existence of OX40-co-stimulated T-cells has been shown to facilitate the development of T-cell memory populations. 25, 26 Using an adoptive transfer model, we used OX40 signaling to modulate the immune status of recipients and found that recipient mice that underwent activation of OX40 signaling, as a means of inhibiting regulatory T-cell function before ACT, demonstrated augmented antitumor effects in their adoptively transferred CD8
1 T-cells. 7 Thus, conditioning recipients by additional OX40 signaling can adjust the immunological environment in favor of antitumor activity. However, little is known about the direct effect of OX40 co-stimulation on the Ag-specific CTLs before use in ACT for the treatment of cancer.
In our study, we assessed the immunological functions of tumor antigen-specific CTLs that were generated using OX40 co-stimulation in vitro and then used for ACT therapy in tumor-bearing mouse recipients.
Material and Methods

Mice
Wild-type FVB mice were selected for the study, as they are more relevant to the clinical setting than knockout or TCR (T cell receptor) transgenic models are. All animals were housed under pathogen-free conditions at Shiga University of Medical Science (Shiga, Japan). Experiments on mice were approved by the Animal Care and Use Committee of Shiga University of Medical Science.
Cell lines
Mammary tumor cell line. The NT cell line, which expresses the immunologically dominant antigen HER-2/neu (neu), was grown in Breast Medium, as previously described. 27 Vaccine cell line. 3T3neu/GM are fibroblasts derived from NIH-3T3 cells genetically modified to express neu and the immunostimulant mouse granulocyte macrophage colony stimulating factor (mGM-CSF). 28, 29 Antigen-presenting cell line. 
Antibodies and peptides
The anti-OX40 monoclonal antibody (mAb) was purified from the supernatant of OX86 hybridoma cultures (European Collection of Cell Cultures, Salisbury, UK). The immunodominant peptide RNEU 420-429 (PDSLRDLSVF) derived from the neu antigen, and another peptide NP 118-126 (RPQASGVYM) derived from a nuclear protein as a control, were purchased from Hokkaido System Science Co. Ltd. (Hokkaido, Japan) with their purity confirmed to be >95%. APC-anti-mouse CD8a, PEanti-mouse IFN-g, PE-anti-mouse CCR7, FITC-anti-mouse IFN-g, FITC-anti-mouse CD62L (BD Pharmingen, San Jose, CA), PE-anti-mouse Bcl-2 and FITC anti-mouse CD27 (BioLegend, San Diego, CA) were used in neu-specific CTLs assays.
Flow cytometry
Flow cytometry data were collected using BD FACSCalibur cytometer (BD Biosciences, Franklin Lakes, NJ) and analyzed using FlowJo software (Tree Star, Inc., Ashland, OR). ), defined as the product of tumor diameters along the orthogonal axes, was recorded every 3 days to evaluate the effect of ACT therapy.
In vitro CTL generation
Frequency of neu-specific CTLs assay
At the indicated times, cultured T-cells or T-cells isolated from the splenocytes of recipient mice were incubated overnight with RNEU-pulsed T2D q cells (ratio 1:1) in 48-well plates at 378C and 5% CO 2 . Intracellular cytokine staining (ICS) was then performed as previously described, 31 using
Cytofix/Cytoperm with Golgistop (BD Pharmingen) to identify the frequency of the IFN-g 1 CD8 1 T-cell response to RNEU by flow cytometry.
Expression of markers in neu-specific CTLs
T-cells cultured for transfer therapy were re-stimulated with RNEU-pulsed T2D q cells as aforementioned, and subjected to ICS, using the appropriate antibodies to assess the percentage of marker expression (CD27, CD62L or CCR7) or mean fluorescence intensity (MFI) of Bcl-2 in IFN-
populations.
Neu-specific CTLs proliferation assay
In vitro proliferation assay. T-cells purified from the spleens of donor FVB mice were labeled with 10 lM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Waltham, MA) before plating into 24-well plates for in vitro CTL generation, using the MHC-I restricted peptide RNEU in the presence or absence of OX40 co-stimulation. Following this, the cultured T-cells were re-stimulated by RNEU-pulsed T2D q cells and assessed by ICS. The population of IFN-g 1 CD8 1 T-cells responding to RNEU-re-stimulation was gated to determine the CFSE dilution of neu-specific CTLs.
In vivo proliferation assay. 
Statistical analysis
Student's t-test was performed as a comparative method, with significance values indicated as follows: *p < 0.05, **p < 0.005. 
Results
Generating tumor antigen-specific CTLs, using a tumor peptide and OX40 co-stimulation T-cells isolated from splenocytes of neu-vaccinated FVB mice were cultured and the frequency of neu-specific CTLs evaluated to determine the optimal culture time. On Day 7 of culture, the percentage of CD8
1 T-cells secreting IFN-g, when re-stimulated with RNEU-pulsed T2D q cells, reached a peak (Fig. 1a) . Therefore, CD8 1 T-cells acquired from T-cells cultured for 7 days were used for T-cell transfer therapy. Next, the number of neu-specific CTLs was increased to allow for more effective ACT therapy, using T-cell culture combined with in vitro OX40 co-stimulation. During 7 days of culture, the T-cells were co-cultured with or without an agonistic anti-OX40 mAb. Although the neu-specific CTLs increased in number after 7 days of culture, contrary to expectations, the neu-specific CD8
1 T-cells co-cultured in the presence of OX40 signaling were fewer than neu-specific CD8 1 T-cells cultured without OX40 signaling (Fig. 1b) .
Culturing T-cells in the presence of OX40 signaling restrains the proliferation of antigen-specific CTLs in vitro
We next examined the proliferation of neu-specific CTLs generated during 7 days of peptide-RNEU stimulation with or without OX40 co-stimulation. CFSE histograms of IFN-g 1 CD8
1
T-cell populations showed less CFSE dilution in cells cultured with OX40 stimulation compared to that in cells cultured without OX40 co-stimulation (Fig. 2) , supporting the result of there being a smaller number of neu-specific CTLs acquired from in vitro generation in the presence of OX40 signaling.
Presence of OX40 signaling during CTL generation drives antigen-specific CTLs toward early differentiation and promotes longevity
Next, the tumor antigen-specific effector CD8 1 T-cells that were generated from T-cell culture in the presence or absence of anti-OX40 mAb in the culture medium were characterized.
Following 7 days of in vitro T-cell culture, the population of generated neu-specific CTLs was identified by ICS and the expression of CD27, CD62L, CCR7 or Bcl-2 on these cells examined.
Compared to cells cultured in the absence of OX40 signaling, the neu-specific CTLs cultured in the presence of OX40 costimulation expressed significantly more CD27, CD62L and CCR7, which indicated that these effector T-cells were at earlier differentiation stages (p 5 0.003, 0.003 and 0.001, respectively). Expression of Bcl-2, an anti-apoptotic protein, was also significantly higher in neu-specific CTLs generated in the presence of OX40 co-stimulation than in those cultured in the absence of OX40 co-stimulation (p 5 0.014; Fig. 3 ).
Adoptive transfer of CD8 1 T-cells co-stimulated by OX40 signaling in vitro shows potent antitumor effects
The anti-tumor effects of CD8 1 T-cells that were cultured with stimulation of a tumor peptide, in the presence or absence of OX40 co-stimulation, were next assessed. Tumorbearing recipient mice received 1 3 10 7 CD8 1 T-cells as ACT on Day 3 after tumor inoculation. The CD8 1 T-cells that had been co-stimulated through the OX40 signaling pathway in vitro contained approximately 5% of RNEUspecific CTLs in 1 3 10 7 CD8 1 T-cells (Fig. 1b) T-cells cultured in the presence of OX40 co-stimulation, could not eliminate the tumor, although a transient delay in tumor growth was observed compared to that in control mice that did not undergo CTL transfer (PBS injection) (Fig. 4) . 1 T-cells reactive to RNEU peptide re-stimulation were assessed by ICS as being neu-specific CTLs. CFSE dilution gated on these CTLs population revealed proliferation profiles over 7 days of in vitro CTL generation, with or without OX40 signaling. Representative data are from one of three separate experiments.
On Day 6 after T-cell transfer, RNEU-specific CTLs were present at higher levels in the spleens of recipient mice that had received CTLs with in vitro OX40 co-stimulation, compared to the levels in mice that had received CTLs without in vitro OX40 co-stimulation, or did not undergo CTL transfer (p < 0.0001 in both; Fig. 5a ).
Tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro can proliferate in tumorbearing recipient mice
To understand the in vivo proliferation capability of the transferred tumor antigen-specific CD8
1 T-cells, we labeled CD8 1 T-cells with CFSE just before transfer of these cells to tumor-bearing recipient mice. On Day 6 after T-cell transfer, we assessed the detectable CFSE-labeled neu-specific CTLs in recipient splenocytes. Neu-specific CTLs that had been generated in vitro in the presence of OX40 co-stimulation demonstrated several peaks in CFSE histogram, whereas neuspecific CTLs cultured in the absence of in vitro OX40 co-stimulation had negligible CFSE dilution (Fig. 6 ). These findings indicate that tumor Ag-specific CTLs generated in the presence of OX40 co-stimulation in vitro maintained the ability to proliferate in a tumor-bearing host after ACT. However, tumor Ag-specific CTLs that were generated in the absence of OX40 co-stimulation lost their proliferative ability in vivo following ACT. 
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Tumor antigen-specific CTLs generated in the presence of OX40 signaling maintain long-term antitumor immune function in recipients On Day 45 post-ACT, RNEU-specific CTLs could be detected in the spleens of recipient mice that received CTLs costimulated by OX40 signaling in vitro (Fig. 5b) , suggesting that the transferred tumor Ag-specific CTLs generated in the presence of OX40 co-stimulation in vitro maintain their long-term antitumor immune function in the recipient and may become memory T-cells.
Discussion
In our study, we found that adoptively transferred tumor Ag-specific CTLs that were generated using tumor antigen stimulation and OX40 co-stimulation in vitro, appeared to be early-state effector cells with increased expression of antiapoptotic molecules, and therefore, these CTLs were able to proliferate and persist in tumor-bearing recipients, thereby providing a long-term antitumor function.
CD27, CD62L or CCR7, well-known T-cell surface markers, is associated with early differentiation of T-cells. 32, 33 Effector T-cells at earlier stages of differentiation have a survival advantage coupled with a high proliferative potential, so they can exist longer in vivo following transfer and suppress tumor growth more effectively than T-cells at later stages of differentiation. [32] [33] [34] [35] In our study, we found an elevation in the levels of CD27, CD62L and CCR7 in OX40-driven tumor Ag-specific effector CD8
1 T-cells. These effector CD8 1 Tcells also possessed more of the anti-apoptotic protein Bcl-2 in their cytoplasm than effector CD8 1 T-cells that were generated without OX40 co-stimulation had. Consequently, after adoptive transfer, these OX40-driven tumor Ag-specific effector CD8 1 T-cells could not only proliferate in a tumorbearing recipient, but also showed enduring tumor Ag-specific effector functions even in the tumor-bearing environment. Moreover, these OX40-driven tumor Ag-specific effector CD8 1 T-cells accumulated in the recipients' spleens after tumor elimination, and persisted as memory T-cells that could be activated after re-stimulation with tumor antigen. Thus, providing OX40 signaling during in vitro tumor antigen stimulation modulates the tumor Ag-specific CTLs to differentiate toward earlier effector states, and provides them with the potential to proliferate and persist due to the expression of anti-apoptotic proteins, as well as to possess a dramatic anti-tumor effect. These findings suggest that in vitro co-stimulation of tumor Ag-specific CTLs with OX40 signaling before transfer is a promising approach to optimize the antitumor ACT therapy.
The enhanced anti-tumor effects caused by OX40 signaling have been reported extensively in studies in which OX40 ligands were administered directly to tumor-bearing subjects. 7, 18, 22, 23, 26, 36 The beneficial results achieved from systemic OX40 co-stimulation in both mice and monkey models 7, 23, 26, 37, 38 led to a phase I clinical trial in which a cycle of an agonistic mouse anti-human OX40 mAb was administered to patients with advanced cancers, as an additional co-stimulation therapy. 39 At a limited dose of anti-OX40 mAb, tumor shrinkage was observed in 12/30 (40%) patients, although toxicity, including lymphopenia, fatigue, rash and anemia, was observed. While this trial strongly suggests the benefit of using an anti-OX40 mAb in the clinical setting, it may also highlight the importance of addressing the toxicity of multiple cycles of anti-OX40 mAb treatment. In this regard, administering the anti-OX40 mAb directly to the CD8 1 T-cells in vitro before transferring to recipients is one strategy that could prevent the systemic toxicities derived from anti-OX40 mAb treatment in patients, while still maintaining the antitumor activity of the tumor-specific CTLs. This new strategy of using direct costimulation of CTLs in vitro before transfer may be applicable in numerous cancer immunotherapies and will be able to reduce the incidence of systemic toxicities as well as the required amount of these expensive molecules.
Tumor Ag-specific CTLs derived from a patient's T-cells are usually difficult to generate and expand to sufficient numbers to allow for elimination of tumors. Thus, our experimental model in which we generated tumor Ag-specific CTLs using T-cells from wild-type mice, where the number of tumor Ag-specific CTLs is much lower than what would be observed in TCR-transgenic mice, is likely to be more clinically relevant. A very important finding in our study is that 5 3 10 5 OX40-driven tumor Ag-specific effector CD8
1 T-cells administered in tumor-bearing mouse could eradicate the tumor, while maintaining their expansion and longevity in vivo, whereas 2.6 times more tumor Ag-specific effector CD8 1 T-cells, that were not OX40-driven, had very limited antitumor effects and showed no expansion in vivo. These findings suggest that appropriate modulation of CTLs, even if they are limited in number, may positively affect CTL function and lead to an effective antitumor outcome in the clinical application of ACT therapy. Our model does have some limitations, especially with regard to analyzing the mechanisms of action. OX40-driven tumor Ag-specific effector CD8
1 T-cells possess the properties of central-memory-like T-cells, including the expression of cell-surface markers, such as CD27, CD62L or CCR7, and their potential for proliferation and long-term persistence. However, because of limited cell number, we could not identify whether the tumor Ag-specific IFN-g 1 CD8 1 T-cells had the phenotype
hi , which is typical for central memory cells. 40 In addition, the very low number of antigen-specific CTLs normally present in wild-type mice prevented us from discovering more about the fate of the transferred CD8
1 T-cells in vivo, particularly with respect to the Figure 5 . Neu-specific CTLs in recipient mice after ACT therapy. Donor T-cells were subjected to neu-specific CTL generation in vitro, with or without OX40 signaling, for 7 days and CD8 1 T-cells were isolated and transferred to tumor-bearing recipient mice as described above. On Day 6 and Day 45 post transfer, T-cells from the spleens of recipient mice that received CD8
1 T-cells generated with or without OX40 costimulation or PBS as a control, were re-stimulated overnight with RNEU or NP peptide-pulsed T2D q cells. ICS was used to assess the IFN- 
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tumor-infiltrating lymphocyte population. Our study provides the first evidence of the benefits of OX40 signaling during tumor Ag-specific CTL generation in vitro for subsequent use in ACT. Further studies using TCR transgenic models with ample sources of tumor Ag-specific CTLs may overcome some of the limitations of this approach.
Endogenous tumor antigen is usually tolerized to endogenous host immune systems. Even though endogenous tumor antigen-specific CTLs are induced in vivo, these CTLs are usually subject to peripheral immune tolerance by immunosuppressive cells, including regulatory T cells and myeloidderived suppressor cells (MDSCs). HER2/neu, the tumor antigen that was used in our model, is of rat origin. Its product, although highly homologous to the mouse protein, is a non-tolerized antigen in mice. As a next step, we intend to investigate whether transferred OX40-stimulated CTLs can overcome the peripheral tolerance to endogenous tumor antigen and elicit antitumor immune response in a tolerized system, such as HER2/neu transgenic mice.
Conclusion
In conclusion, tumor Ag-specific CTLs that were generated in vitro in the presence of an MHC-class I-restricted peptide and OX40 co-stimulation have the ability to eradicate tumors, and the potential for expansion and maintenance in vivo. The strategy of modulating tumor Ag-specific CTLs in vitro using specific immune modulators, such as OX40, before adoptive transfer is expected to increase the efficacy of ACT therapy, decreasing the required amount of these expensive molecules, and reducing toxicities in the recipient, all of which will hopefully simplify clinical translation into patients with cancer. Figure 6 . CFSE dilution of transferred neu-specific CTLs on Day 6 post ACT therapy. Donor T-cells were cultured with RNEU-pulsed T2D q cells, with or without OX40 signaling, for 7 days and CD8
1 T-cells were isolated from the cultures. These CD8 1 T-cells were labeled with CFSE prior to being transferred to tumor-bearing recipient mice. Six days later, T-cells from the spleens of recipient mice that had been transferred with CD8
1 T-cells generated with or without OX40 co-stimulation or PBS as a control, were re-stimulated with the RNEU peptide to verify the neu-specific CTLs populations. These populations were gated and examined for their CFSE dilution to allow an assessment of cell proliferation. Representative data are from one of the two separate experiments. There were four mice in each group.
